PT - JOURNAL ARTICLE AU - Chidharla, Anusha AU - Rapoport, Eliot AU - Agarwal, Kriti AU - Madala, Samragnyi AU - Linares, Brenda AU - Sun, Weijing AU - Chakrabarti, Sakti AU - Kasi, Anup TI - Circulating Tumor DNA As A MRD Assessment And Recurrence Risk In Patients Undergoing Curative Intent Resection With Or Without Adjuvant Chemotherapy In Colorectal Cancer: A Meta-analysis AID - 10.1101/2022.11.04.22281967 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.04.22281967 4099 - http://medrxiv.org/content/early/2022/11/07/2022.11.04.22281967.short 4100 - http://medrxiv.org/content/early/2022/11/07/2022.11.04.22281967.full AB - PURPOSE Emerging data have suggested that circulating tumor DNA (ctDNA) can be a reliable biomarker for Minimal residual disease (MRD) in CRC patients. Recent studies have shown that the ability to detect MRD using ctDNA assay after curative-intent surgery will change how to assess recurrence risk and patient selection for adjuvant chemotherapy.METHODS We performed a meta-analysis of post-operative ctDNA in Stage I-IV (oligometastatic) CRC patients after curative-intent resection. We included 23 studies representing 3,568 patients with evaluable ctDNA in CRC patients post-curative intent surgery. Data were extracted from each study to perform a meta-analysis using RevMan 5.4. software. Subsequent subgroup analysis was performed for stages I-III and oligometastatic stage IV CRC patients.RESULTS The pooled hazard ratio (HR) for recurrence-free survival (RFS) in post-surgical ctDNA positive versus negative patients in all stages was 7.27 (95% CI 5.49-9.62) p <0.00001. Subgroup analysis revealed pooled HR of 8.14 (95% CI 5.60-11.82) and 4.83 (95% CI 3.64-6.39) for stage I-III and IV CRC, respectively. The pooled HR for RFS in post-adjuvant chemotherapy ctDNA positive versus negative patients in all stages was 10.59 (95% CI 5.59-20.06) p <0.00001. The subgroup analysis based on the ctDNA method showed a pooled HR of 8.66 (95% CI 6.38-11.75) and 3.76 (95% CI 2.58-5.48) for tumor-informed and tumor-agnostic, respectively.CONCLUSION Our analysis emphasizes that post-operative ctDNA is a strong prognostic marker of RFS. Based on our results, ctDNA can be a significant and independent predictor of RFS. This real-time assessment of treatment benefits using ctDNA can be used as a surrogate endpoint for the development of novel drugs in the adjuvant setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript.